

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Said I.A. SHALABY et al.

Serial No.

09/955,877

Examiner

Patten, Patricia A.

Filed

September 19, 2001

Group Art Unit:

1654

For

HERBAL COMPOSITIONS AND TREATMENT METHODS

LETTER ENCLOSING COPIES OF IDS DOCUMENTS

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS: Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

May 24, 2004

Date of Deposit

Rochelle K. Seide Attorney Name 32,300

PTO Registration No.

Signature

May 24, 2004

Date of Signature

Mail Stop: Issue Fee Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Further to the telephonic interview that Applicant's representatives had with the Examiner on April 14, 2004, Applicants submit herewith copies of the documents cited in the Information Disclosure Statement (IDS) and Form PTO-1449 filed on January 22, 2004. The Examiner indicated that she would mail a Notice of Allowance, but would still consider the documents in Applicants IDS and Form PTO-1449 if copies were expeditiously provided.

NY02:485852.1 1

Applicants have discovered several minor typographical errors in the IDS and Form PTO-1449 filed on January 22, 2004. Therefore, Applicants have enclosed herewith a marked-up Form PTO-1449 showing the corrections. In addition, to ensure that the cover of any patent issuing from this application correctly cites the documents cited, Applicants have also enclosed a substitute Form PTO-1449 incorporating the corrections. Applicants have further included copies of the January 22, 2004 IDS and Form PTO-1449 for the Examiner's convenience.

While Applicants do not believe any fee is due with this submission, the Commissioner is hereby authorized to deduct any fees required with this submission not otherwise enclosed herewith from Deposit Account No. 02-4377. Two copies of a Fee Transmittal are enclosed.

Respectfully submitted,

BAKER BOTTS, L.L.P.

May 24, 2004

Rochelle K. Seide PTO Reg. No. 32,300

Carmella L. Stephens PTO Reg. No. 41,328 Attorneys for Applicants

Guy F. Birkenmeier PTO Reg. No. 52,622 Agent for Applicants

BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, NY 10112 (212) 408-2500

Enclosures

2



Applicants have discovered several minor typographical errors in the IDS and

Form PTO-1449 filed on January 22, 2004. Therefore, Applicants have enclosed herewith a marked-up Form PTO-1449 showing the corrections. In addition, to ensure that the cover of any patent issuing from this application correctly cites the documents cited, Applicants have also enclosed a substitute Form PTO-1449 incorporating the corrections. Applicants have further included copies of the January 22, 2004 IDS and Form PTO-1449 for the Examiner's convenience.

While Applicants do not believe any fee is due with this submission, the Commissioner is hereby authorized to deduct any fees required with this submission not otherwise enclosed herewith from Deposit Account No. 02-4377. Two copies of a Fee Transmittal are enclosed.

Respectfully submitted,

BAKER BOTTS, L.L.P.

May 24, 2004

Rochelle K. Seide PTO Reg. No. 32,300

Carmella L. Stephens PTO Reg. No. 41,328 Attorneys for Applicants

Guy F. Birkenmeier PTO Reg. No. 52,622 Agent for Applicants

BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, NY 10112 (212) 408-2500

Enclosures

BAKER BOTTS LLR

1	6	~′
		B

MAY 2 6 2004 BY

lease type a plus sign (+) inside this box 🛶 🛨

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/955,877
Filing Date	September 19, 2001
First Named Inventor	Said I.A. SHALABY et al.
Group Art Unit	1654
Examiner Name	Patten, Patricia A.
Attorney Docket Number	AP32738 066876.0103

-	ENCLOSURES (check	call that apply)			
Fee Transmittal Form	Assignment Papers (for an Application)	After Allowance Communication to Group			
Fee Attached	Drawing(s)	Appeal Communication to Board of Appeals and Interferences			
Amendment / Reply	Licensing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Petition	Proprietary Information			
Affidavits/declaration(s)	Petition to Convert to a Provisional Application	Status Letter			
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address	Other Enclosure(s) (please identify below):			
Express Abandonment Request	Terminal Disclaimer Request for Refund	See attached sheet			
Information Disclosure Statement	CD, Number of CD(s)				
Certified Copy of Priority Document(s)	Remarks				
Response to Missing Parts/ Incomplete Application	Tronding				
Response to Missing Parts					
under 37 CFR 1.52 or 1.53					
SIGNA	URE OF APPLICANT, ATTORNEY, OR	AGENT			
Firm BakerBotts LLF					
or 30 Rockefeller	7.1				
Individual name New York, NY	7 - 1				
Signature Kollu	lu K Slede PTO Reg:	Rochelle K. Seide 32,300			
Date May 24, 2004	·				
	CERTIFICATE OF MAILING				

	CERTIFICATE OF MAILING
I hereby certify that this correspo mail in an envelope addressed to	ndence is being deposited with the United States Postal Service with sufficient postage as first class commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date: May 24, 2004
Typed or printed name	Rochelle K. Seide
Signature	M Villette X Mell Date May 24, 2004

BAKER BOTTS LLP

Attorney Docket Number: AP32738 066876.0103

Title:

HERBAL COMPOSITIONS AND TREATMENT METHODS

Use Space Below for Additional Information:

This submission includes:

Transmittal (2 pages);

Fee Transmittal (1 sheet in duplicate);

Letter Enclosing Copies of IDS Documents (2 pages);

Substitute Form PTO-1449 (3 pages);

Marked-up Form PTO-1449 (3 pages);

Copy of previous Form PTO-1449 (3 pages);

Copy of previous IDS (4 pages);

Copies of 27 IDS documents (1 bound volume);

Return Postcard

MAN 2 6 2004 BASKER BOTTS LLE

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$) 0

C	Complete if Known	
Application Number	09/955,877	
Filing Date	September 19, 2001	
First Named Inventor	Said I.A. SHALABY et al.	
Examiner Name	Patten, Patricia A.	
Art Unit	1654	
Attorney Docket No.	AP32738 066876.0103	

(4/0	Attorney Docket No. AF 32730 000070.0103			
METHOD OF PAYMENT (check all that apply)	METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)			
Check Credit card Money Other None	3. ADDITIONAL FEES			
Deposit Account:	Large Entity Small Entity			
Deposit OO 4077	Fee Fee Fee Fee Fee Description	Fee Paid		
Account Number	1051 130 2051 65 Surcharge - late filing fee or oath			
Deposit Account Baker Botts LLP	1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet			
Name The Commissioner is authorized to: (check all that apply)	1053 130 1053 130 Non-English specification			
Charge fee(s) indicated below Credit any overpayments	1812 2,520 1812 2,520 For filing a request for ex parte reexaminat	ion		
Charge any additional fee required under 37CFR 1.16 and 1.17	1804 920° 1804 920° Requesting publication of SIR prior to Examiner action			
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action			
<u>'</u>	1251 110 2251 55 Extension for reply within first month			
FEE CALCULATION	1252 420 2252 210 Extension for reply within second month			
1. BASIC FILING FEE Large Entity Small Entity	1253 950 2253 475 Extension for reply within third month			
Fee Fee Fee Fee Description Fee Paid	1254 1,480 2254 740 Extension for reply within fourth month			
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee	1255 2,010 2255 1,005 Extension for reply within fifth month			
1002 340 2002 170 Design filing fee	1401 330 2401 165 Notice of Appeal			
1003 530 2003 265 Plant filing fee	1402 330 2402 165 Filing a brief in support of an appeal			
1004 770 2004 385 Reissue filing fee	1403 290 2403 145 Request for oral hearing			
1005 160 2005 80 Provisional filing fee	1451 1,510 1451 1,510 Petition to institute a public use proceeding	9		
SUBTOTAL (1) (\$) 0	1452 110 2452 55 Petition to revive - unavoidable			
	1453 1,300 2453 650 Petition to revive - unintentional			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501 1,330 2501 665 Utility issue fee (or reissue)			
Extra Claims below Fee Paid	1502 480 2502 240 Design issue fee			
Total Claims	1503 630 2503 315 Plant issue fee			
Independent	1460 130 1460 130 Petitions to the Commissioner			
	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806 180 1806 180 Submission of Information Disclosure Stm	'		
Code (\$) Code (\$)	8021 40 8021 40 Recording each patent assignment per property (times number of properties)			
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 Independent claims in excess of 3	1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))			
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 2810 385 For each additional invention to be			
1204 86 2204 43 ** Reissue independent claims	examined (37 CFR 1.129(b))			
over original patent	1801 770 2801 385 Request for Continued Examination (RCI	=)		
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900 1802 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 0	Other fee (specify)			
**or number previously paid,-if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)0			
SUBMITTED BY	(Complete (if applicable)			
Name (Print/Type) Rochelle K. Seide / /	Registration No. (Attorney/Agent) 32,300 Telephone 212.408.2	2500		
	L Date May 24, 2			

Substitut	te				.c./)					P	age 1 of	3
Form PT (REV. 2-	TO-1449 -82) Pa	U.	Depar	### Date Date		Atty. Docket No. AP32738 066876.0103		al No. 955,877					
INFO	RMAT						STA	TEMENT	Applicant Said I.A. SHALABY et a	ıl			
	(Use						ssar	y)	Filing Date September 19, 2001	Grov 165			-
								U.S. PATEN	T DOCUMENTS				
*Exam.			Docur	nent N	o.			Date	Name '	Class	Subclass	Filing Da	
Init.	5	8	7	6	7	2	8	03/02/1999	Kass HD et al.			ПАрргорг	rate
-	5	8	7	4	8	0	4	02/23/1999	Rogers SP				
	5	6	4	8	0	8	9	07/15/1997	Shawkat T				
		<u> </u>					L.					<u></u>	
								FOREIGN PA	TENT DOCUMENT			T:	
			Docur	nent N	o.			Date	Country	Class	SubClass	<u>Trans</u> Yes	<u>lator</u> No
		7	9	1		6	4	09/10/1999	Europe (EP)	*			
					•								
											<u> </u>		
				отн	ER D	OCL	JMEI	NTS (including	Author, Title Date, Pertinent	Pages, Etc.))		
		Ha	rvard	Schoo	ol of l	Public	Hea	lth Jan 2004, <h< td=""><td>ttp://www.researchmatters.harva</td><td>ard.edu/story</td><td>.php?article</td><td>:_id=673></td><td></td></h<>	ttp://www.researchmatters.harva	ard.edu/story	.php?article	:_id=673>	
									arrhea as a surrogate model of h):1-15;	epatitis C vi	rus for the e	valuation	of
		Co De	st of I	Develor 8, 2	oping 2003	a Ne <http:< td=""><td>w Dri //onli</td><td>ne.wsj.com/artic</td><td>About \$1.7 Billion By PETER L cle/0,,SB107083909136415400-</td><td>ANDERS , email,00.htm</td><td>Wall Street nl></td><td>Journal</td><td></td></http:<>	w Dri //onli	ne.wsj.com/artic	About \$1.7 Billion By PETER L cle/0,,SB107083909136415400-	ANDERS , email,00.htm	Wall Street nl>	Journal	
		Ab	ramo	wicz I	M, ed	., "En	fuvirt	ide (Fuzeon) fo	r HIV Infection" Med Lett Drug	s Ther. 2003	3 Jun 23; 45	(1159): 49	-50;
		El-	Awad	ly, et	al., C	linica	Chin	nica Acta, 283(1	2):1-14 (1999);				

NY02:472768.1

Examiner Date Considered

McHutchison et al., "Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment fro Chronic

Hepatitis C", New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Substitute MAY 2 6 2004		
Form PTO-1449 U. Department of Commerce (REV. 2-82) Patent and Theoretical Office	Atty. Docket No. AP32738 066876.0103	Serial N 09/955

REV. 2-82) Patent and Thomas ark Office	AP32738 066876.0103	09/955,877
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Said I.A. SHALABY et al.	

BY APPLICANT			_
(Use several sheets if necessary)	Filing Date September 19, 2001	Group 1654	
			_

Page 2 of 3

Yokozawa, et al., J. Traditional Medicine, 15(1):45-51 (1998)
Alter, M.J., Hepatology, 26(1):62S-65S (1997)
Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);
D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);
Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);
D.C. Dale and D.D. Federman, eds., Sci. Amer. Medicine, New York, 4(8):1-10 (1996);
Hibbs, et al., J. Infect. Dis. 168:789-790 (1993);
Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);
Flint SJ et al., Principles of Virology: Molecular Biology, Pathogenesis, and Control, ASM Press, Washington DC, 1990, p.691;
Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);
Medicinal Plants of North Africa, pp. 74-75, 92-93 (1983);
Bergmeyer and Horder, Clinica Chemica Acta 105:147f-154f (1980);
Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, John Wiley & Sons, New York, p.169 (1980);
International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Clin. Biochem., 18:521-534 (1980);


NY02:472768.1

Examiner Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

bstitute (- MAY 2 6 2004)		Page 3 of 3
orm PTO-1449 U.S. Department of Commerce REV. 2-82) Paten and Trademark Office	Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Said I.A. SHALABY et al.	
(Use several sheets if necessary)	Filing Date September 19, 2001	Group 1654
Bergmeyer H. U. Methods of Enzymatic Ana	alysis. Verlag Chemic, (1978), pp. 13	0-135;
Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970);	
Linus Pauling, General Chemistry, New York	k, Dover Publications, Inc., 1970, p	744.
7 02:472768.1		
aminer Dat	te Considered	

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Said I.A. SHALABY et al.

Serial No.

09/955,877

Examiner

Patten, Patricia A.

Filed

September 19, 2001

Group Art Unit:

1654

For

HERBAL COMPOSITIONS AND TREATMENT METHODS

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

January 22, 2004
Date of Deposit

Carmella L. Stephens

41,328

Attorney Name

PTO Registration No.

armun & Stephens

Signature

January 22, 2004

Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

• In accordance with 37 C.F.R. §1.56, Applicant respectfully requests that the documents relating to the above-identified application listed herein in reverse chronological alphabetical order be considered and made of record in the U.S. Patent and Trademark Office.

1. Harvard School of Public Health Jan 2004,

http://www.researchmatters.harvard.edu/story.php?article_id=673;

NY02:472756.1 1



- Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis
 C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
- Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER
 LANDERS, Wall Street Journal December 8, 2003
 http://online.wsj.com/article/0, SB107083909136415400-email, 00.html>;
- 4. Enfuvirtide (Fuzeon) for HIV Infection Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
- 5. Abd El-Baset M et al, EP 0793964 published September 10, 1999;
- 6. El-Awady, et al., Chem. Clinical Acta, 283(1-2):1-14 (1999);
- 7. Kass HD et al., U.S. Patent No. 5,876,728 issued March 2, 1999;
- 8. Rogers SP, U.S. Patent No. 5,874,804 issued February 23, 1999;
- McHutchison et al Interferon Alpha-2b Alone or in Combination with Ribavirin as
 Initial Treatment fro Chronic Hepatitis C, New England Journal of Medicine Vol 339

 Number 21 November 19, 1998, 1485-1492;
- 10. Yokozbawa, et al., J. Traditional Medicine, 15(4):202-207 (1998);
- 11. Alter, M.J., Hepatology, 26(1):625-655 (1997);
- 12. Shawkat T, U.S. Patent No. 5,648,089 issued July 15, 1997;
- 13. Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);
- 14. D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);
- 15. Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);
- 16. D.C. Dale and D.D. Federman, eds. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);
- 17. Hipps, et al., Infect. Dis. 168:789-790 (1993);

NY02:472756.1 2



- 18. Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);
- 19. Fields, Virology 2nd ed, New York, Raven Press, 1990 p691;
- 20. Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);
- 21. Medicinal Plants of North Africa, pp. 74-75 (1983);
- 22. Bergmeyer and Horder, Clin. Chen. Acta 105147 f. (1980);
- 23. Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, p.169 (1980);
- 24. International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Biochem., 18:521-534 (1980);
- 25. Bergmeyer H. U. Principles of Enzymatic Analysis. Verlag Chemic, (1978);
- 26. Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970); and
- 27. Linus Pauling, General Chemistry, New York, Raven Press 1970, p 744.

The referenced citations are listed in the accompanying PTO Form 1449. Copies of the documents will follow as soon as they are available. Identification of the documents listed in the attached PTO Form 1449 is not to be construed as an admission of Applicants or Attorneys for Applicants that such documents are available as "prior art" against the above-identified application.

NY02:472756.1 3

Applicants enclose herewith the fees required pursuant to 37 C.F.R. §§ 1.17(p)

and 1.97(c)(2). Applicants do not believe any additional fee is due with this submission.

Nevertheless, the Commissioner is hereby authorized to deduct any fees required with this submission not otherwise enclosed herewith from Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,

BAKER BOTTS, L.L.P.

January 22, 2004

Rochelle K. Seide PTO Reg. No. 32,300

Carmella L. Stephens PTO Reg. No. 41,328 Attorneys for Applicants

Guy F. Birkenmeier PTO Reg. No. 52,622 Agent for Applicants

BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, NY 10112 (212) 408-2500